Navigation Links
Vanda Presents Phase III Iloperidone Efficacy Data
Date:12/12/2007

lease contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended September 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014 Imago ... today announced a $26.5 million Series A financing ... firm founded by a team of accomplished investment ... investors participating in the round include Frazier Healthcare, ... Representatives from Clarus Ventures and Frazier Healthcare will ...
(Date:10/31/2014)... ARBOR, Mich. , Oct. 31, 2014 /PRNewswire/ ... immune modulators to treat autoimmune disease and cancer, ... of novel synthetic RORgamma agonist product candidates will ... Society for Immunotherapy of Cancer (SITC) being held ... & Convention Center, National Harbor, MD.  The poster, ...
(Date:10/31/2014)... 31, 2014 Investor-Edge has initiated ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow ...
Breaking Medicine Technology:Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
... HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - ... a new 42 month follow-up study of ... evaluated symptomatic,progress of U.S. patients involved in ... 2003. Individuals in the study were assessed,for ...
... at American Association for Cancer Research ... /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, Inc. , a ... commercializing proprietary product,candidates for the treatment ... positive results from preclinical studies using ...
Cached Medicine Technology:Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 3Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 4
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review ... fat loss program ever developed. It promises to provide users ... is no wonder after all that this has become the ... nutrition and workout fat loss program was created by Joel ... to the author of this fat loss system, the method ...
(Date:10/31/2014)... At the start of 2014, numerous ... carbon monoxide poisoning in their homes. Now, as 2015 ... family-owned, Missouri-based heating and cooling company is taking a ... start the home heating season with the assurance that ... Beginning Nov. 1, 2014, E and Q Heating and ...
(Date:10/31/2014)... Energy Textiles has recently added a ... is now available online, and Energy Textile is providing ... infrared-active athletic gear over compression gear. , The ... been signed for Under Armour to provide team gear ... years. In light of this decision, Energy Textiles contemplates ...
(Date:10/31/2014)... -- Obesity increases the risk of certain types of ... new U.S. studies show. One study of more ... increased the risk for estrogen receptor-negative and progesterone receptor-positive ... for a long time for white women, but now ... author Esther John, a senior research scientist at the ...
(Date:10/31/2014)... one out of four older Americans say that either ... unwanted medical treatment, according to the latest issue of ... Aging Report ( PP&AR ), which goes on ... when they fail to honor patients, end-of-life health care ... Illness Care: Issues and Options ," features 12 articles ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Advance directives can benefit patients, families, and health care system 2
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
... for Patient-Provider Decision MakingFurther Action Needed to Ensure ... Senate today improved on a comparative effectiveness research ... $1.1 billion dollar research effort on clinical effectiveness," ... of the National Alliance for Hispanic Health, the ...
... Ringling Bros.(R) Conservation and Breeding ProgramVIENNA, Va., Jan. 27 ... Elephant Conservation (R) proudly announces the ... twenty-second birth in what has proven to be the most ... importantly, this is the first calf in the Ringling ...
... Healthcare Realty,Trust Incorporated (NYSE: HR ) ... the market closes, it will report results for the ... February 24, 2009, at 9:00 a.m. Central Time, Healthcare ... results, quarterly activities,general operations of the Company and industry ...
... has completed a new study on uric acid and C8 and ... increased uric acid is associated with higher levels of C8 and ... can cause an increase in uric acid.The Science Panel team recently ... (also known as PFOA) and C8S (also known as PFOS) in ...
... St. Jude Children,s Research Hospital and the Children,s Oncology ... leukemia (ALL) scores of inherited genetic variations that clinicians ... more effective chemotherapy for this cancer. ... rates for ALL exceed 80 percent, patient responses vary ...
Cached Medicine News:Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3Health News:Statement on Comparative Effectiveness Research Under Senate Appropriations Committee Stimulus Bill 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 3Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 4Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 5Health News:Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call 2Health News:C8 Science Panel Completes Uric Acid Study 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 3
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
... is a simultaneous vision lens ... Through a series of front ... LifeStyle Gp delivers up to ... its multi-aspheric center-distance design works ...
Gendron ophthalmic eye surgery stretcher....
... surgical stretcher. M-701 Stretcher has a ... to 32 in., measured with a ... a high range, 28 in. to ... pad can be supplied optionally. Vinyl ...
Medicine Products: